George Elston - 25 May 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Financial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
25 May 2024
Net transactions value
-$40,477
Form type
4
Filing time
28 May 2024, 16:22:48 UTC
Previous filing
13 Feb 2024
Next filing
07 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +7,500 +17% $0.000000 51,107 25 May 2024 Direct
transaction EYPT Common Stock Tax liability $40,477 -3,627 -7.1% $11.16 47,480 25 May 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -7,500 -33% $0.000000 15,000 25 May 2024 Common Stock 7,500 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.
F2 The restricted stock units vest in three ratable annual installments beginning May 25, 2024.